Background: We just right were carrying out a multicenter cohort study about ICH when COVID-19 broke out in Wuhan，and we wondered whether COVID-19 pandemic was associated with the manifestations and outcomes of intracerebral hemorrhage (ICH). Methods: Acute ICH patients before (1/12/2018-30/11/2019) and during COVID-19(1/12/2019-30/11/2020) pandemic at 31 centers in China, were entered into the analysis. Demographic information, clinical manifestations and outcomes were collected and compared between the two groups. Results: From December 1, 2018 to November 30, 2020, a total of 3460 patients with ICH were enrolled and eventually analyzed. Results showed that patients with ICH were more likely to be older, have higher systolic blood pressure (BP) (P<0.001), diastolic-BP (P=0.002), higher admission NIHSS score (P=0.039) and higher fasting blood glucose (P=0.003) during COVID-19 pandemic compared with before. After adjusting age, gender, COVID-19 pandemic was associated with 3-month poor outcome (OR adjusted = 1.206, 95%CI: 1.043-1.395) and 3-month mortality (OR adjusted = 1.711, 95%CI: 1.428-2.050) after ICH onset. Conclusions: COVID-19 pandemic deteriorated the manifestations and outcomes of ICH.

Aims: We aim to find out the factors affecting the use of anticoagulants and the intensity of their choices, and to establish a basis for improving neurologists’ effective implementation of the guidelines. Methods: A cross-sectional study is conducted in Hubei province in central China. Each neurologist completes a standard-structured anonymous questionnaire through face-to-face interviews. The problems include the attitude and options about anticoagulant therapy. Results: A total of 611 neurologists from 38 hospitals respond to this survey. For the best treatment of atrial fibrillation, more than 80% of physicians choose anticoagulant therapy. For patients with atrial fibrillation and cerebral infarction, physicians think Warfarin is the preferred drug as high as 93.8%. Among the anticoagulant drugs ever used by clinicians, the use rate of Warfarin is 93.8%, but the use rate of direct oral anticoagulants is extremely low. The use of direct oral anticoagulants is related to the educational level and the geographical location of the hospital. Bleeding risk is the first reason influencing clinicians’ choice of Warfarin, accounts for 88.9%. 97.7% of the clinicians recommend patients with Warfarin regularly monitoring the INR, but the frequency of monitoring is inconsistent. Clinicians have a high willingness to learn about AF, but the proportion of hospitals carry out appropriate training is low. Conclusions: There are still some gaps with the guidelines on the choice of anticoagulant drugs. Neurologists have positive attitude towards anticoagulant therapy and a strong willingness to learn, but the corresponding training is lacking. Continuous professional training is necessary.